<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:24:11Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6750650" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6750650</identifier>
        <datestamp>2019-09-27</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6750650</article-id>
              <article-id pub-id-type="pmcid">PMC6750650</article-id>
              <article-id pub-id-type="pmc-uid">6750650</article-id>
              <article-id pub-id-type="pmid">31532789</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0222178</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-19-05686</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Response</subject>
                      <subj-group>
                        <subject>Antibody Response</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Response</subject>
                      <subj-group>
                        <subject>Antibody Response</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Infectious Disease Control</subject>
                      <subj-group>
                        <subject>Vaccines</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Routes of Administration</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Viral Diseases</subject>
                      <subj-group>
                        <subject>Influenza</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Immune Physiology</subject>
                      <subj-group>
                        <subject>Antibodies</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Immune Physiology</subject>
                      <subj-group>
                        <subject>Antibodies</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System Proteins</subject>
                      <subj-group>
                        <subject>Antibodies</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System Proteins</subject>
                      <subj-group>
                        <subject>Antibodies</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Proteins</subject>
                      <subj-group>
                        <subject>Immune System Proteins</subject>
                        <subj-group>
                          <subject>Antibodies</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Public and Occupational Health</subject>
                    <subj-group>
                      <subject>Preventive Medicine</subject>
                      <subj-group>
                        <subject>Vaccination and Immunization</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and immunization</subject>
                      <subj-group>
                        <subject>DNA vaccination</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and health sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and immunization</subject>
                      <subj-group>
                        <subject>DNA vaccination</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and health sciences</subject>
                  <subj-group>
                    <subject>Public and occupational health</subject>
                    <subj-group>
                      <subject>Preventive medicine</subject>
                      <subj-group>
                        <subject>Vaccination and immunization</subject>
                        <subj-group>
                          <subject>DNA vaccination</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>People and Places</subject>
                  <subj-group>
                    <subject>Population Groupings</subject>
                    <subj-group>
                      <subject>Age Groups</subject>
                      <subj-group>
                        <subject>Elderly</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial</article-title>
                <alt-title alt-title-type="running-head">Seasonal influenza DNA vaccine is safe and immunogenic in healthy adults</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Carter</surname>
                    <given-names>Cristina</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Visualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2147-186X</contrib-id>
                  <name>
                    <surname>Houser</surname>
                    <given-names>Katherine V.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Visualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yamshchikov</surname>
                    <given-names>Galina V.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bellamy</surname>
                    <given-names>Abbie R.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>May</surname>
                    <given-names>Jeanine</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Enama</surname>
                    <given-names>Mary E.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sarwar</surname>
                    <given-names>Uzma</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Larkin</surname>
                    <given-names>Brenda</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bailer</surname>
                    <given-names>Robert T.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Koup</surname>
                    <given-names>Richard</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Grace L.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patel</surname>
                    <given-names>Shital M.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Winokur</surname>
                    <given-names>Patricia</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Belshe</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dekker</surname>
                    <given-names>Cornelia L.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Graham</surname>
                    <given-names>Barney S.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2047-6052</contrib-id>
                  <name>
                    <surname>Ledgerwood</surname>
                    <given-names>Julie E.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Visualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>the VRC 703 study team</collab>
                  <xref ref-type="author-notes" rid="fn001">
                    <sup>¶</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>The Emmes Corporation, Rockville, MD, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Departments of Medicine and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Division of Infectious Diseases, Allergy and Immunology, Saint Louis University, St. Louis, MO, United States of America</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Department of Pediatrics (Infectious Diseases), Stanford University Medical Center, Stanford, CA, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Fast</surname>
                    <given-names>Patricia Evelyn</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>IAVI, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The Emmes Corporation provided support in the form of salaries for authors AB and JM but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. This support does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
                </fn>
                <fn fn-type="other" id="fn001">
                  <p>¶ Membership of the VRC 703 study team can be found in the Acknowledgments.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>Ledgerwood@mail.nih.gov</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>18</day>
                <month>9</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2019</year>
              </pub-date>
              <volume>14</volume>
              <issue>9</issue>
              <elocation-id>e0222178</elocation-id>
              <history>
                <date date-type="received">
                  <day>26</day>
                  <month>2</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>28</day>
                  <month>7</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">
                  <license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0222178.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>Seasonal influenza results in significant morbidity and mortality worldwide, but the currently licensed inactivated vaccines generally have low vaccine efficacies and could be improved. In this phase 1 clinical trial, we compared seasonal influenza vaccine regimens with different priming strategies, prime-boost intervals, and administration routes to determine the impact of these variables on the resulting antibody response.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods</title>
                  <p>Between August 17, 2012 and January 25, 2013, four sites enrolled healthy adults 18–70 years of age. Subjects were randomized to receive one of the following vaccination regimens: trivalent hemagglutinin (HA) DNA prime followed by trivalent inactivated influenza vaccine (IIV3) boost with a 3.5 month interval (DNA-IIV3), IIV3 prime followed by IIV3 boost with a 10 month interval (IIV3-IIV3), or concurrent DNA and IIV3 prime followed by IIV3 boost with a 10 month interval (DNA/IIV3-IIV3). Each regimen was additionally stratified by an IIV3 administration route of either intramuscular (IM) or intradermal (ID). DNA vaccines were administered by a needle-free jet injector (Biojector). Study objectives included evaluating the safety and tolerability of each regimen and measuring the antibody response by hemagglutination inhibition (HAI).</p>
                </sec>
                <sec id="sec003">
                  <title>Results</title>
                  <p>Three hundred and sixteen subjects enrolled. Local reactogenicity was mild to moderate in severity, with higher frequencies recorded following DNA vaccine administered by Biojector compared to IIV3 by either route (p &lt;0.02 for pain, swelling, and redness) and following IIV3 by ID route compared to IM route (p &lt;0.001 for swelling and redness). Systemic reactogenicity was similar between regimens. Though no overall differences were observed between regimens, the highest titers post boost were observed in the DNA-IIV3 group by ID route and in the IIV3-IIV3 group by IM route.</p>
                </sec>
                <sec id="sec004">
                  <title>Conclusions</title>
                  <p>All vaccination regimens were found to be safe and tolerable. While there were no overall differences between regimens, the DNA-IIV3 group by ID route, and the IIV3-IIV3 group by IM route, showed higher responses compared to the other same-route regimens.</p>
                </sec>
              </abstract>
              <funding-group>
                <funding-statement>This clinical study was conducted with funding and support by the National Institute of Allergy and Infectious Diseases (NIAID) Intramural Research program, using resources provided by the American Recovery and Reinvestment Act of 2009 (Recovery Act), and contract #HHSN272201000049I awarded to the Emmes Corporation (AB, JM, SP, PW, RB, CD). The Clinical and Translational Research Unit at Stanford University was supported by an NIH/NCRR CTSA award UL1 RR025744. The Emmes Corporation and other funders provided support in the form of salaries for authors AB and JM but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="4"/>
                <table-count count="4"/>
                <page-count count="18"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the manuscript and its Supporting Information files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec005">
              <title>Introduction</title>
              <p>In the United States, seasonal influenza results in significant disease burden, with estimated ranges of 114,018–633,001 hospitalizations and 4,866–27,810 deaths each year [<xref rid="pone.0222178.ref001" ref-type="bibr">1</xref>]. Vulnerable populations, including older adults, are more susceptible to experiencing severe complications following influenza infection [<xref rid="pone.0222178.ref001" ref-type="bibr">1</xref>–<xref rid="pone.0222178.ref003" ref-type="bibr">3</xref>]. A recent survey spanning three consecutive influenza seasons found that between 54–70% of hospitalizations and 71–85% of deaths occur among adults above 65 years of age [<xref rid="pone.0222178.ref001" ref-type="bibr">1</xref>]. Even in young healthy adults where infection severity is typically milder, illness still results in substantial economic impact through absence from work and healthcare visits [<xref rid="pone.0222178.ref004" ref-type="bibr">4</xref>].</p>
              <p>Vaccination is currently the most effective way to protect the population and lessen influenza disease burden. Licensed seasonal influenza vaccines include inactivated, live attenuated, and recombinant vaccines [<xref rid="pone.0222178.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0222178.ref006" ref-type="bibr">6</xref>]. The trivalent (IIV3) and quadrivalent (IIV4) inactivated influenza vaccines are updated annually to include hemagglutinin (HA) proteins from two circulating influenza A strains (H1N1 and H3N2) and one or two influenza B strains [<xref rid="pone.0222178.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0222178.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0222178.ref008" ref-type="bibr">8</xref>]. Inactivated vaccines can be administered by either the intramuscular (IM) route for individuals ≥6 months or by the intradermal (ID) route in adults 18–64 years old [<xref rid="pone.0222178.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0222178.ref009" ref-type="bibr">9</xref>]. While inactivated vaccines are the most widely administered, randomized controlled trials indicate inactivated vaccine efficacies typically range between only 62–75% for healthy adults, and just 43% for older adults [<xref rid="pone.0222178.ref010" ref-type="bibr">10</xref>–<xref rid="pone.0222178.ref013" ref-type="bibr">13</xref>]. Additional disadvantages to inactivated vaccines include a labor-intensive manufacturing process and, with the exception of recombinant and cell-based vaccines, most require embryonated eggs for production [<xref rid="pone.0222178.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0222178.ref015" ref-type="bibr">15</xref>].</p>
              <p>DNA vaccines are an alternative vaccine platform that may improve immune responses and overcome the aforementioned disadvantages of inactivated influenza vaccines [<xref rid="pone.0222178.ref016" ref-type="bibr">16</xref>]. DNA vaccines consist of plasmids which can be easily modified through recombinant technology, and then rapidly developed and produced. While there are no licensed DNA vaccines to date, they do have an excellent safety profile, as demonstrated in multiple phase 1 clinical trials examining West Nile, SARS, influenza, and Zika [<xref rid="pone.0222178.ref017" ref-type="bibr">17</xref>–<xref rid="pone.0222178.ref030" ref-type="bibr">30</xref>]. Vaccination regimens consisting of a DNA prime followed by a heterologous inactivated boost have been previously explored as a strategy to improve immunogenicity for both seasonal and avian influenza subtypes. To date, such regimens have resulted in improved antibody responses for avian subtypes including H5 and H7 [<xref rid="pone.0222178.ref017" ref-type="bibr">17</xref>–<xref rid="pone.0222178.ref020" ref-type="bibr">20</xref>], but not for seasonal influenza subtypes [<xref rid="pone.0222178.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0222178.ref022" ref-type="bibr">22</xref>]. Timing of the prime-boost interval after a DNA prime has proven important for optimal antibody responses against novel antigens, including avian influenza subtypes. Antibody responses following DNA priming were higher after an inactivated boost with an interval of 3–6 months compared to an interval of only 1 month [<xref rid="pone.0222178.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0222178.ref020" ref-type="bibr">20</xref>]. However, the optimal prime-boost interval between a DNA prime and inactivated boost in seasonal influenza is unknown. Another question of interest for seasonal influenza is whether priming with a DNA and inactivated vaccine concurrently may result in an improved antibody response after an inactivated boost. Previously, a concurrent prime resulted in similar HAI titers to a DNA prime alone for an avian H7 subtype [<xref rid="pone.0222178.ref017" ref-type="bibr">17</xref>].</p>
              <p>In this phase 1 clinical trial, we compared different priming strategies, prime-boost intervals, and routes of administration to determine whether these variables impacted the antibody response. Specifically, we evaluated whether priming with a DNA vaccine alone or concurrently with an inactivated vaccine would affect the antibody response following an inactivated boost in the same or subsequent influenza season. Additionally, we assessed the antibody response of the regimens in older adults to determine if a DNA prime would improve the vaccine response following an inactivated boost in this population.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec006">
              <title>Materials and methods</title>
              <sec id="sec007">
                <title>Ethics statement</title>
                <p>This study was a phase 1 open-label randomized clinical trial in healthy adults (clinicaltrials.gov, NCT01676402) to compare vaccination schedules over the same or subsequent influenza season (<xref ref-type="fig" rid="pone.0222178.g001">Fig 1</xref>). The study enrolled subjects at four sites, and the institutional review board (IRB) at each site approved the trial protocol (Baylor College of Medicine IRB approved the trial on July 3, 2012, University of Iowa on July 17, 2012, Saint Louis University on July 11, 2012, and Stanford University Medical Center on August 24, 2012). Subjects for this study were recruited by each site in accordance with their site IRB standard for recruitment practices. Enrollment for the trial occurred between August 17, 2012 and January 25, 2013, and the last subject visit occurred on April 25, 2014. Each subject signed a written informed consent prior to study participation. The trial registration on clinicaltrials.gov occurred on August 30, 2012, adhering to 42 CFR Part 11 requirements by occurring within 21 days of enrolling the first subject. The trial followed guidelines for conducting clinical research with human subjects from the US Department of Health and Human Services and was performed in accordance with 45 CFR Part 46, US Food and Drug Administration regulations for investigational products, and principles expressed in the Declaration of Helsinki.</p>
                <fig id="pone.0222178.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0222178.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>CONSORT diagram for VRC 703 clinical trial.</title>
                    <p>Each group was stratified by age: younger adults (18–50 years) and older adults (51–70 years for IM or 51–64 for ID). All subjects who received at least one vaccination (n = 316) were analyzed for safety and reactogenicity. All subjects who completed the vaccination schedule (n = 299) were also analyzed for immunogenicity.</p>
                  </caption>
                  <graphic xlink:href="pone.0222178.g001"/>
                </fig>
              </sec>
              <sec id="sec008">
                <title>Study design and participants</title>
                <p>Subjects were randomized in this clinical trial into groups through a staggered enrollment plan. Groups 1 and 2 (same influenza season regimens) consisted of a 2012/13 trivalent HA DNA prime and 2012/13 IIV3 boost administered by either ID or IM route with an approximate interval of 3.5 months (DNA-IIV3 regimen) (<xref ref-type="fig" rid="pone.0222178.g001">Fig 1</xref>, <xref rid="pone.0222178.t001" ref-type="table">Table 1</xref>). The 3.5 month interval was chosen based on results from previous phase 1 trials investigating DNA vaccines of avian influenza subtypes which indicated that an improved antibody response is achieved with a 3–6 months interval between DNA prime and inactivated boost [<xref rid="pone.0222178.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0222178.ref020" ref-type="bibr">20</xref>]. The trial was designed to allow for the prime-boost interval to be shortened in the DNA prime groups (groups 1 and 2 only) when there was a local outbreak of influenza in the community, so that subjects would be able to receive a licensed product while the trial was ongoing. The interval was shortened for 10 subjects at a single site (4 subjects in group 1 and 6 subjects in group 2), and these subjects were included with the remainder of their groups in the immunogenicity analysis. Groups 3 to 6 (subsequent influenza season regimens) consisted of a prime of either 2012/13 IIV3 alone administered by either ID or IM route (groups 3 and 4) or with a concurrent HA DNA vaccine in the opposite arm (groups 5 and 6). These subjects were then boosted with 2013/14 IIV3 using the same route of administration as the IIV3 prime, with an approximate interval of 10 months (IIV3-IIV3 and DNA/IIV3-IIV3 regimens, respectively). Each group was stratified by age: younger adults (18–50 years) and older adults (51–70 years for IM or 51–64 years for ID). The age ranges in the older adults are consistent with the FDA approval for the IIV3 products [<xref rid="pone.0222178.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0222178.ref031" ref-type="bibr">31</xref>]. Other inclusion criteria included a BMI less than 40 and no prior receipt of the 2012/13 seasonal influenza vaccine. A complete listing of eligibility criteria is provided in the study protocol in the supplementary materials (<xref ref-type="supplementary-material" rid="pone.0222178.s002">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0222178.s003">S2</xref> Protocols).</p>
                <table-wrap id="pone.0222178.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0222178.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Vaccine regimens and intervals of each group.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0222178.t001g" xlink:href="pone.0222178.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="2" style="background-color:#F0F0F0" colspan="1">Group</th>
                          <th align="center" rowspan="2" style="background-color:#F0F0F0" colspan="1">IIV3 route<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref></th>
                          <th align="center" colspan="2" style="background-color:#F0F0F0" rowspan="1">Vaccine Regimen</th>
                          <th align="center" rowspan="2" style="background-color:#EDEDED" colspan="1">Prime-boost Interval</th>
                        </tr>
                        <tr>
                          <th align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">Prime</th>
                          <th align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">Boost</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">
                            <bold>1</bold>
                          </td>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">ID</td>
                          <td align="center" rowspan="2" colspan="1">4mg HA DNA</td>
                          <td align="center" rowspan="2" colspan="1">2012/13 seasonal IIV3</td>
                          <td align="center" rowspan="2" style="background-color:#FFFFFF" colspan="1">3.5 months</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">
                            <bold>2</bold>
                          </td>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">IM</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">
                            <bold>3</bold>
                          </td>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">ID</td>
                          <td align="center" rowspan="2" colspan="1">2012/13 seasonal IIV3</td>
                          <td align="center" rowspan="2" colspan="1">2013/14 seasonal IIV3</td>
                          <td align="center" rowspan="4" style="background-color:#FFFFFF" colspan="1">10 months</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">
                            <bold>4</bold>
                          </td>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">IM</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">
                            <bold>5</bold>
                          </td>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">ID</td>
                          <td align="center" rowspan="2" colspan="1">HA DNA and<break/>2012/13 seasonal IIV3</td>
                          <td align="center" rowspan="2" colspan="1">2013/14 seasonal IIV3</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">
                            <bold>6</bold>
                          </td>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">IM</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p><sup>a</sup> Each administration of IIV3 by IM route contains 45mg total HA, while IIV3 by ID route contains 27mg total HA</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Subjects self-reported local and systemic reactogenicity on a diary card for seven days after each vaccination, after receiving guidance on the grading of each symptom during the vaccination visit. All adverse events were recorded for 28 days following each vaccination. Serious adverse events (SAE) and influenza-like illnesses (ILI) were recorded for the entire duration of the trial.</p>
              </sec>
              <sec id="sec009">
                <title>Vaccines</title>
                <p>The investigational 2012/13 trivalent seasonal HA DNA (VRC-FLUDNA063-00-VP) consisted of identical amounts by weight of three DNA plasmids designed to closely match the recommended HA sequences contained within the licensed seasonal 2012/13 IIV3: VRC-9328 (A/California/04/2009, [A(H1N1)pdm09]), VRC-3027 (A/Victoria/361/2011, H3N2), and VRC-2722 (B/Wisconsin/1/2010) (<xref rid="pone.0222178.t002" ref-type="table">Table 2</xref>). The trivalent HA DNA vaccine was manufactured at the NIAID Vaccine Research Center Vaccine Pilot Plant using Good Manufacturing Practices and formulated at 4mg/mL in PBS. The authors confirm that all ongoing and related trials for this product are registered.</p>
                <table-wrap id="pone.0222178.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0222178.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Influenza strains included in the vaccines.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0222178.t002g" xlink:href="pone.0222178.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" style="background-color:#F0F0F0" rowspan="1" colspan="1">Vaccine</th>
                          <th align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">A(H1N1)pdm09</th>
                          <th align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">H3N2</th>
                          <th align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">B</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">
                            <bold>2012/13 HA DNA</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">A/California/04/2009</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">A/Victoria/361/2011</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">B/Wisconsin/1/2010</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">
                            <bold>2012/13 seasonal IIV3</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">A/California/07/2009</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">A/Victoria/361/2011-like</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">B/Wisconsin/1/2010-like: B/Texas/6/2011</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#EDEDED" rowspan="1" colspan="1">
                            <bold>2013/14 seasonal IIV3</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">A/California/07/2009</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">A/Texas/50/2012</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">B/Massachusetts/2/2012</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
                <p>Fluzone (Sanofi Pasteur) was the licensed seasonal IIV3 used for IM (0.5mL, 45mg total HA) and ID (0.1mL, 27mg total HA) administration for both influenza seasons. The strains in the seasonal 2012/13 IIV3 included A/California/07/2009 [A(H1N1)pdm09], A/Victoria/361/2011-like virus (H3N2), and B/Wisconsin/1/2010-like: B/Texas/6/2011 (<xref rid="pone.0222178.t002" ref-type="table">Table 2</xref>). The strains in the seasonal 2013/14 IIV3 included A/California/07/2009 [A(H1N1)pdm09], A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (<xref rid="pone.0222178.t002" ref-type="table">Table 2</xref>).</p>
                <p>All DNA vaccines were administered into the deltoid muscle using a needle-free jet injector, Biojector 2000 (Bioject; Tualatin, OR, USA). IIV3 was administered in the deltoid muscle either by ID route using a supplied short-needle microinjection system (groups 1, 3, and 5) or IM route using a needle and syringe (groups 2, 4, and 6).</p>
              </sec>
              <sec id="sec010">
                <title>Randomization and masking</title>
                <p>The study followed a staggered enrollment plan, with the same influenza season regimens enrolling first. In this first part, subjects were randomized with equal allocation to groups 1 or 2. Randomization was then opened to the subsequent influenza season regimens with equal allocation to groups 3 to 6. The randomization was staggered so that all subjects could receive the seasonal 2012/13 IIV3 at approximately the same time, soon after it became available. Subjects 65–70 years of age were enrolled only into groups 2, 4, and 6 to ensure IIV3 administration by the IM route. The randomization sequence was generated by the trial statistician using permuted blocked randomization with randomly selected block sizes (2 or 4 in the first part, 4 or 8 in the second part), stratified by age and site. Upon enrollment, each subject’s randomized assignment was displayed in the electronic data entry system and vaccinations were administered open-label.</p>
              </sec>
              <sec id="sec011">
                <title>Immunogenicity assays</title>
                <p>Blood samples were collected prior to each vaccination, 3 weeks after both the prime and boost vaccinations, and 6 months after the boost. Subject sera were tested for antibody response by hemagglutination inhibition (HAI). HAI assays were completed at Southern Research, Inc. (Birmingham, AL) using previously described validated methods [<xref rid="pone.0222178.ref021" ref-type="bibr">21</xref>]. Briefly, the HAI assays were performed in V-bottom 96-well plates with four HA units of virus and 0.5% turkey red blood cells.</p>
              </sec>
              <sec id="sec012">
                <title>Statistical analysis</title>
                <p>The primary objectives of the study were (1) to assess the safety and tolerability of each vaccination schedule, including concurrent prime of DNA and IIV3 in different arms, and (2) to compare the antibody responses by HAI at 3 weeks after IIV3 administration between the DNA-IIV3 regimen and IIV3 alone. The primary outcomes of safety and tolerability were measured by a combination of solicited and unsolicited reactogenicity for 7 days following each vaccination, and the occurrence of adverse events, serious adverse events, and influenza-like illnesses for the duration of the trial. Solicited reactogenicity included pain/tenderness, swelling, redness, malaise, myalgia, headache, chills, nausea, and temperature. Secondary objectives included evaluating HAI antibody titers in all groups at 3 weeks after each study injection. We analyzed all outcomes on the basis of the intention-to-treat principle. All subjects who received at least one vaccination were analyzed for safety and reactogenicity. All subjects who completed the vaccination schedule were also analyzed for immunogenicity. This trial was designed as a descriptive study with a planned enrollment of 55 subjects per group. The study was not designed to test a formal null hypothesis for superiority or non-inferiority. With the planned sample size, the study was likely to detect event occurring with high frequency (&gt;90% chance to observe at least one safety event if the true rate is at least 0.05 (1 of 20), but would be unlikely (&gt;90% chance of observing no events) occurring at a rate less than 0.002 (1 of 500). This minimum group size allowed for 80% power with significance level 5% to detect a 28% difference in seroconversion rates between two groups if the proportion of responders in the reference group was 40%.</p>
                <p>The seroconversion rate for HAI was determined per the FDA definition as either a baseline (Day 0) HAI titer &lt;1:10 and a post boost HAI titer ≥1:40, or a baseline HAI titer ≥1:10 and a minimum four-fold rise from baseline [<xref rid="pone.0222178.ref032" ref-type="bibr">32</xref>]. The magnitude of immune response was calculated as the geometric mean titer (GMT). Comparisons were made between overall groups and between age groups within each overall group. A Fisher’s exact test was used for comparisons of seroconversion rates and the t-test was used to compare magnitudes of log-transformed HAI titers. The primary analysis adjusted for the effect of site using the logistic (seroconversion outcome) and analysis of variance (log-transformed titer response outcome). Chi-square tests were used to compare the distribution of solicited symptom severity between groups. Statistical significance was considered at a level of alpha = 0.05. Adjustment for multiple comparisons was not performed as statistical inferences in this small phase 1 clinical trial are hypothesis-generating, and not confirming. Statistical analyses were performed in SAS 9.3 (SAS Institute, Cary, North Carolina).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec013">
              <title>Results</title>
              <sec id="sec014">
                <title>Study population and vaccine safety</title>
                <p>A total of 316 subjects were enrolled in the study between August 17, 2012 and January 25, 2013 (<xref ref-type="fig" rid="pone.0222178.g001">Fig 1</xref>). The group demographics are displayed in <xref rid="pone.0222178.t003" ref-type="table">Table 3</xref>. Overall, there were 125 (39.6%) males and 191 (60.4%) females, with an average age of 41 years. Study vaccinations were completed by 299 subjects (94.6%), and 293 subjects (92.7%) completed the protocol. Reasons for the 23 subjects who did not complete the protocol include: ineligible due to previous receipt of 2012/13 IIV3, failure to disclose hepatitis C infection, withdrawal after diagnosis of pancreatic cancer (unrelated SAE), death by myocardial infarction (unrelated SAE), unrelated ongoing fatigue, and subjects moved or were lost to follow up.</p>
                <table-wrap id="pone.0222178.t003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0222178.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>Baseline demographics of participants.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0222178.t003g" xlink:href="pone.0222178.t003"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="2" colspan="1"><break/>Characteristics</th>
                          <th align="center" colspan="6" rowspan="1">Treatment Group</th>
                          <th align="center" rowspan="2" colspan="1">Overall<break/>(n = 316)</th>
                        </tr>
                        <tr>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Group 1<break/>DNA/IIV3 ID route<xref ref-type="table-fn" rid="t004fn002"><sup>a</sup></xref><break/>(n = 53)</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Group 2<break/>DNA/IIV3 IM route<break/>(n = 57)</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Group 3<break/>IIV3/IIV3 ID route<break/>(n = 50)</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Group 4<break/>IIV3/IIV3 IM route<break/>(n = 56)</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Group 5<break/>DNA-IIV3/IIV3<break/>ID route<break/>(n = 48)</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Group 6<break/>DNA-IIV3/IIV3<break/>IM route<break/>(n = 52)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" colspan="8" style="background-color:#EDEDED" rowspan="1">
                            <bold>Sex - no. (%)</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Male</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">21 (39.6)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">22 (38.6)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">19 (38.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">20 (35.7)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">20 (41.7)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">23 (44.2)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">125 (39.6)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Female</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">32 (60.4)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">35 (61.4)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">31 (62.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">36 (64.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">28 (58.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">29 (55.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">191 (60.4)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="8" style="background-color:#EDEDED" rowspan="1">
                            <bold>Age - years</bold>
                            <xref ref-type="table-fn" rid="t004fn003">
                              <sup>
                                <bold>b</bold>
                              </sup>
                            </xref>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Mean (SD)</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">39.4 (14)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">42.4 (17)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41.9 (14)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41.9 (16)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">40.2 (15)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41.2 (15)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41.2 (15)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Range</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">[20, 63]</td>
                          <td align="left" rowspan="1" colspan="1">[20, 70]</td>
                          <td align="left" rowspan="1" colspan="1">[19, 62]</td>
                          <td align="left" rowspan="1" colspan="1">[18, 69]</td>
                          <td align="left" rowspan="1" colspan="1">[18,63]</td>
                          <td align="left" rowspan="1" colspan="1">[18, 64]</td>
                          <td align="left" rowspan="1" colspan="1">[18, 70]</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="8" style="background-color:#EDEDED" rowspan="1">
                            <bold>Race - no. (%)</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>American Indian/Alaskan Native</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (1.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0.3)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Asian</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (5.7)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4 (7.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">5 (10.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (3.6)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">5 (10.4)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4 (7.7)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">23 (7.3)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Black or African American</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (3.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4 (7.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (12.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (1.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">5 (10.4)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (11.5)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">24 (7.6)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Native Hawaiian/Pacific Islander</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>White</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">44 (83.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">47 (82.5)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">38 (76.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">47 (83.9)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">35 (72.9)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41 (78.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">252 (79.7)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Multiracial</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4 (7.5)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (2.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">5 (8.9)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (6.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (1.9)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">14 (4.4)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Other/Unknown</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (1.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (1.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (0.6)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="8" style="background-color:#EDEDED" rowspan="1">
                            <bold>Ethnicity - no. (%)</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Non-Hispanic/Latino</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">50 (94.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">52 (91.2)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">48 (96.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">50 (89.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">47 (97.9)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">50 (96.2)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">297 (94.0)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Hispanic/Latino</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (5.7)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">5 (8.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (4.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (10.7)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (2.1)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (3.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">19 (6.0)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="8" style="background-color:#EDEDED" rowspan="1">
                            <bold>Body Mass Index (BMI)</bold>
                            <xref ref-type="table-fn" rid="t004fn004">
                              <sup>
                                <bold>c</bold>
                              </sup>
                            </xref>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Mean (SD)</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.8 (4.9)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">25.9 (4.4)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">25.8 (5.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.3 (5.1)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.4 (4.9)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.4 (4.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.2 (4.7)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Range</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">[17.2, 38.3]</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">[19.1, 35.1]</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">[18.3, 38.3]</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">[18.6, 38.5]</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">[18.5, 38.2]</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">[19.3, 35.6]</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">[17.2, 38.5]</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="8" style="background-color:#EDEDED" rowspan="1">
                            <bold>Influenza vaccinations in the previous 5 years - no. (%)</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>&gt;5 times</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4 (7.5)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">11 (19.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10 (20.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (14.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (12.5)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10 (19.2)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">49 (15.5)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>3–5 times</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">22 (41.5)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">24 (42.1)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">18 (3.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">21 (37.5)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26 (54.2)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">18 (34.6)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">129 (40.8)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>1–2 times</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">19 (35.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">15 (26.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">9 (18.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">15 (26.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10 (20.8)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10 (19.2)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">78 (24.7)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>0 times</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (15.1)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7 (12.3)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (26.0)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">12 (21.4)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (12.5)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">14 (26.9)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">60 (19.0)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t003fn001">
                      <p><sup>a</sup>Route only pertains to IIV3 vaccine. DNA vaccines were administered by Biojector.</p>
                    </fn>
                    <fn id="t003fn002">
                      <p><sup>b</sup>Age represents age at enrollment (date of prime vaccination).</p>
                    </fn>
                    <fn id="t003fn003">
                      <p><sup>c</sup>Height and weight (used for BMI) measured at Day 0.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>All local reactogenicity was mild to moderate in severity (<xref rid="pone.0222178.t004" ref-type="table">Table 4</xref>). DNA prime administered by Biojector (groups 1, 2, 5 and 6) resulted in significantly higher frequencies of pain and tenderness, redness, and swelling compared to IIV3 by either route (groups 3, 4, 5 and 6) (p &lt;0.02 for all symptoms). IIV3 administered by the ID route resulted in significantly higher frequencies of redness and swelling compared to IIV3 administered by IM route (p &lt;0.001 for both redness and swelling). There was one report of a severe headache following concurrent DNA/IIV3 prime when IIV3 was administered by the ID route and one report of a fever of 102.3°F following IIV3 boost by the ID route that coincided with reports of ILIs in the subjects. One subject reported a combination of severe malaise, headache, and nausea following IIV3 boost by the ID route with no related illness. All of these events resolved without sequelae. Otherwise, systemic reactogenicity was similar among all groups (<xref ref-type="supplementary-material" rid="pone.0222178.s004">S1 Table</xref>).</p>
                <table-wrap id="pone.0222178.t004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0222178.t004</object-id>
                  <label>Table 4</label>
                  <caption>
                    <title>Summary of solicited local reactogenicity after prime and boost vaccination.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0222178.t004g" xlink:href="pone.0222178.t004"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="2" colspan="1">Symptoms<break/>Intensity</th>
                          <th align="center" rowspan="2" colspan="1">Group 1<break/>DNA/IIV3 ID (N = 53/N = 51)<xref ref-type="table-fn" rid="t004fn002"><sup>a</sup></xref></th>
                          <th align="center" rowspan="2" colspan="1">Group 2<break/>DNA/IIV3 IM (N = 57/N = 56)</th>
                          <th align="center" rowspan="2" colspan="1">Group 3<break/>IIV3-IIV3 ID (N = 50/N = 45)</th>
                          <th align="center" rowspan="2" colspan="1">Group 4<break/>IIV3-IIV3 IM (N = 56/N = 55)</th>
                          <th align="center" colspan="2" rowspan="1">Group 5<break/>DNA/IIV3-IIV3 ID<break/>(N = 48/N = 45)<xref ref-type="table-fn" rid="t004fn003"><sup>b</sup></xref></th>
                          <th align="center" colspan="2" rowspan="1">Group 6<break/>DNA/IIV3-IIV3 IM<break/>(N = 52/N = 47)<xref ref-type="table-fn" rid="t004fn003"><sup>b</sup></xref></th>
                        </tr>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">DNA</th>
                          <th align="center" rowspan="1" colspan="1">IIV3</th>
                          <th align="center" rowspan="1" colspan="1">DNA</th>
                          <th align="center" rowspan="1" colspan="1">IIV3</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#F0F0F0" rowspan="1">
                            <bold>Prime Vaccination</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#EDEDED" rowspan="1">
                            <bold>PAIN/TENDERNESS</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>None</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">4 (7.5%)</td>
                          <td align="left" rowspan="1" colspan="1">10 (17.5%)</td>
                          <td align="left" rowspan="1" colspan="1">19 (38.0%)</td>
                          <td align="left" rowspan="1" colspan="1">26 (46.4%)</td>
                          <td align="left" rowspan="1" colspan="1">7 (14.6%)</td>
                          <td align="left" rowspan="1" colspan="1">21 (43.8%)</td>
                          <td align="left" rowspan="1" colspan="1">9 (17.3%)</td>
                          <td align="left" rowspan="1" colspan="1">26 (50.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Mild</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">47 (88.7%)</td>
                          <td align="left" rowspan="1" colspan="1">41 (71.9%)</td>
                          <td align="left" rowspan="1" colspan="1">31 (62.0%)</td>
                          <td align="left" rowspan="1" colspan="1">29 (51.8%)</td>
                          <td align="left" rowspan="1" colspan="1">38 (79.2%)</td>
                          <td align="left" rowspan="1" colspan="1">25 (52.1%)</td>
                          <td align="left" rowspan="1" colspan="1">38 (73.1%)</td>
                          <td align="left" rowspan="1" colspan="1">25 (48.1%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Moderate</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">2 (3.8%)</td>
                          <td align="left" rowspan="1" colspan="1">6 (10.5%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (1.8%)</td>
                          <td align="left" rowspan="1" colspan="1">3 (6.3%)</td>
                          <td align="left" rowspan="1" colspan="1">2 (4.2%)</td>
                          <td align="left" rowspan="1" colspan="1">5 (9.6%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (1.9%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#EDEDED" rowspan="1">
                            <bold>SWELLING</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>None</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">49 (92.5%)</td>
                          <td align="left" rowspan="1" colspan="1">51 (89.5%)</td>
                          <td align="left" rowspan="1" colspan="1">32 (64.0%)</td>
                          <td align="left" rowspan="1" colspan="1">56 (100.0%)</td>
                          <td align="left" rowspan="1" colspan="1">42 (87.5%)</td>
                          <td align="left" rowspan="1" colspan="1">28 (58.3%)</td>
                          <td align="left" rowspan="1" colspan="1">47 (90.4%)</td>
                          <td align="left" rowspan="1" colspan="1">52 (100.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Mild</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">4 (7.5%)</td>
                          <td align="left" rowspan="1" colspan="1">5 (8.8%)</td>
                          <td align="left" rowspan="1" colspan="1">16 (32.0%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">4 (8.3%)</td>
                          <td align="left" rowspan="1" colspan="1">18 (37.5%)</td>
                          <td align="left" rowspan="1" colspan="1">5 (9.6%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Moderate</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (1.8%)</td>
                          <td align="left" rowspan="1" colspan="1">2 (4.0%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">2 (4.2%)</td>
                          <td align="left" rowspan="1" colspan="1">2 (4.2%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#EDEDED" rowspan="1">
                            <bold>REDNESS</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>None</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">48 (90.6%)</td>
                          <td align="left" rowspan="1" colspan="1">53 (93.0%)</td>
                          <td align="left" rowspan="1" colspan="1">15 (30.0%)</td>
                          <td align="left" rowspan="1" colspan="1">54 (96.4%)</td>
                          <td align="left" rowspan="1" colspan="1">41 (85.4%)</td>
                          <td align="left" rowspan="1" colspan="1">26 (54.2%)</td>
                          <td align="left" rowspan="1" colspan="1">44 (84.6%)</td>
                          <td align="left" rowspan="1" colspan="1">52 (100.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Mild</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">5 (9.4%)</td>
                          <td align="left" rowspan="1" colspan="1">4 (7.0%)</td>
                          <td align="left" rowspan="1" colspan="1">26 (52.0%)</td>
                          <td align="left" rowspan="1" colspan="1">2 (3.6%)</td>
                          <td align="left" rowspan="1" colspan="1">6 (12.5%)</td>
                          <td align="left" rowspan="1" colspan="1">18 (37.5%)</td>
                          <td align="left" rowspan="1" colspan="1">7 (13.5%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Moderate</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">9 (18.0%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (2.1%)</td>
                          <td align="left" rowspan="1" colspan="1">4 (8.3%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (1.9%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#EDEDED" rowspan="1">
                            <bold>ANY LOCAL SYMPTOM</bold>
                            <xref ref-type="table-fn" rid="t004fn004">
                              <sup>
                                <bold>c</bold>
                              </sup>
                            </xref>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>None</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">3 (5.7%)</td>
                          <td align="left" rowspan="1" colspan="1">10 (17.5%)</td>
                          <td align="left" rowspan="1" colspan="1">6 (12.0%)</td>
                          <td align="left" rowspan="1" colspan="1">26 (46.4%)</td>
                          <td align="left" colspan="2" rowspan="1">2 (4.2%)</td>
                          <td align="left" colspan="2" rowspan="1">3 (5.8%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Mild</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">48 (90.6%)</td>
                          <td align="left" rowspan="1" colspan="1">41 (71.9%)</td>
                          <td align="left" rowspan="1" colspan="1">34 (68.0%)</td>
                          <td align="left" rowspan="1" colspan="1">29 (51.8%)</td>
                          <td align="left" colspan="2" rowspan="1">37 (77.1%)</td>
                          <td align="left" colspan="2" rowspan="1">43 (82.7%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Moderate</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">2 (3.8%)</td>
                          <td align="left" rowspan="1" colspan="1">6 (10.5%)</td>
                          <td align="left" rowspan="1" colspan="1">10 (20.0%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (1.8%)</td>
                          <td align="left" colspan="2" rowspan="1">9 (18.8%)</td>
                          <td align="left" colspan="2" rowspan="1">6 (11.5%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#EDEDED" rowspan="1">
                            <bold>Boost Vaccination</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#EDEDED" rowspan="1">
                            <bold>PAIN/TENDERNESS</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>None</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">20 (39.2%)</td>
                          <td align="left" rowspan="1" colspan="1">26 (46.4%)</td>
                          <td align="left" rowspan="1" colspan="1">18 (40.0%)</td>
                          <td align="left" rowspan="1" colspan="1">30 (54.5%)</td>
                          <td align="left" colspan="2" rowspan="1">21 (46.7%)</td>
                          <td align="left" colspan="2" rowspan="1">28 (59.6%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Mild</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">31 (60.8%)</td>
                          <td align="left" rowspan="1" colspan="1">30 (53.6%)</td>
                          <td align="left" rowspan="1" colspan="1">26 (57.8%)</td>
                          <td align="left" rowspan="1" colspan="1">25 (45.5%)</td>
                          <td align="left" colspan="2" rowspan="1">23 (51.1%)</td>
                          <td align="left" colspan="2" rowspan="1">19 (40.4%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Moderate</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (2.2%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" colspan="2" rowspan="1">1 (2.2%)</td>
                          <td align="left" colspan="2" rowspan="1">0 (0.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#EDEDED" rowspan="1">
                            <bold>SWELLING</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>None</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">39 (76.5%)</td>
                          <td align="left" rowspan="1" colspan="1">55 (98.2%)</td>
                          <td align="left" rowspan="1" colspan="1">31 (68.9%)</td>
                          <td align="left" rowspan="1" colspan="1">54 (98.2%)</td>
                          <td align="left" colspan="2" rowspan="1">33 (73.3%)</td>
                          <td align="left" colspan="2" rowspan="1">47 (100.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Mild</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">11 (21.6%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (1.8%)</td>
                          <td align="left" rowspan="1" colspan="1">11 (24.4%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (1.8%)</td>
                          <td align="left" colspan="2" rowspan="1">8 (17.8%)</td>
                          <td align="left" colspan="2" rowspan="1">0 (0.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Moderate</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1 (2.0%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" colspan="2" rowspan="1">0 (0.0%)</td>
                          <td align="left" colspan="2" rowspan="1">0 (0.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#EDEDED" rowspan="1">
                            <bold>REDNESS</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>None</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">17 (33.3%)</td>
                          <td align="left" rowspan="1" colspan="1">55 (98.2%)</td>
                          <td align="left" rowspan="1" colspan="1">17 (37.8%)</td>
                          <td align="left" rowspan="1" colspan="1">53 (96.4%)</td>
                          <td align="left" colspan="2" rowspan="1">23 (51.1%)</td>
                          <td align="left" colspan="2" rowspan="1">46 (97.9%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Mild</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">23 (45.1%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (1.8%)</td>
                          <td align="left" rowspan="1" colspan="1">16 (35.6%)</td>
                          <td align="left" rowspan="1" colspan="1">2 (3.6%)</td>
                          <td align="left" colspan="2" rowspan="1">16 (35.6%)</td>
                          <td align="left" colspan="2" rowspan="1">1 (2.1%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Moderate</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">11 (21.6%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" rowspan="1" colspan="1">12 (26.7%)</td>
                          <td align="left" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" colspan="2" rowspan="1">6 (13.3%)</td>
                          <td align="left" colspan="2" rowspan="1">0 (0.0%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="9" style="background-color:#EDEDED" rowspan="1">
                            <bold>ANY LOCAL SYMPTOM</bold>
                            <xref ref-type="table-fn" rid="t004fn004">
                              <sup>
                                <bold>c</bold>
                              </sup>
                            </xref>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>None</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (15.7%)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26 (46.4%)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (13.3%)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">29 (52.7%)</td>
                          <td align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">12 (26.7%)</td>
                          <td align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">28 (59.6%)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Mild</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">32 (62.7%)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">30 (53.6%)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26 (57.8%)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26 (47.3%)</td>
                          <td align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">25 (55.6%)</td>
                          <td align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">19 (40.4%)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Moderate</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">11 (21.6%)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (28.9%)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0.0%)</td>
                          <td align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">8 (17.8%)</td>
                          <td align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">0 (0.0%)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t004fn001">
                      <p>For participants reporting a symptom on multiple days, the symptom is counted once at the maximum severity.</p>
                    </fn>
                    <fn id="t004fn002">
                      <p><sup>a</sup>(N = # subjects receiving prime vaccination/N = # subjects receiving boost vaccination)</p>
                    </fn>
                    <fn id="t004fn003">
                      <p><sup>b</sup>Groups 5 and 6 received a prime vaccination that included 2012/13 IIV3 administered in one arm and HA DNA vaccine in the opposite arm, allowing for the collection of distinct solicited local reactogenicity</p>
                    </fn>
                    <fn id="t004fn004">
                      <p><sup>c</sup>Any Local Symptom displays the summation of the individually listed solicited local reactogenicity</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>There were eight SAEs reported during the trial, and all were evaluated as unrelated to the study vaccines. There were 15 reported cases of ILI during the trial; however, no testing was conducted to distinguish influenza infection from other etiologies.</p>
              </sec>
              <sec id="sec015">
                <title>Preexisting antibody responses were present in all groups</title>
                <p>Prior to vaccination, all groups had preexisting antibody titers by HAI to the influenza vaccine antigens included in the analysis (<xref ref-type="supplementary-material" rid="pone.0222178.s005">S2 Table</xref>). The proportion of subjects with baseline titers of ≥1:40 were similar across groups with the following ranges: 35–45% for A/California/07/2009 [A(H1N1)pdm09], 16–26% for A/Victoria/361/2011 (H3N2), and 40–47% for A/Texas/50/2012 (H3N2). Preexisting responses to influenza B strains were lower: 14–26% for both B/Wisconsin/1/2010 and B/Texas/6/2011, and 8–21% to B/Massachusetts/2/2012. Individual baseline titers were not found to have a significant impact on the response to the vaccine regimens in the trial.</p>
              </sec>
              <sec id="sec016">
                <title>DNA priming resulted in higher antibody GMTs and response rates following IIV3 boost compared to a single administration of IIV3 by the ID route</title>
                <p>The primary immunogenicity objective was to compare whether the addition of DNA priming would affect the magnitude of the antibody response or seroconversion rates of a single administration of IIV3. To achieve this, two groups of subjects received a DNA prime followed by an IIV3 boost (DNA-IIV3 regimen) approximately 3.5 months later by either ID route (group 1) or IM route (group 2) (<xref rid="pone.0222178.t001" ref-type="table">Table 1</xref>). Low antibody GMTs and seroconversion rates were observed following DNA prime prior to IIV3 administration (<xref ref-type="supplementary-material" rid="pone.0222178.s005">S2</xref> and <xref ref-type="supplementary-material" rid="pone.0222178.s006">S3</xref> Tables), consistent with previous studies demonstrating that single administrations of DNA vaccines encoding soluble protein antigens do not significantly boost preexisting antibody responses [<xref rid="pone.0222178.ref023" ref-type="bibr">23</xref>]. To compare the antibody response following completion of the DNA-IIV3 regimen to a single administration of IIV3, we evaluated the antibody response after the IIV3 boost in groups 1 and 2 to the antibody response at 3 weeks following the IIV3 prime vaccination in groups 3 (IIV3 by ID route) and 4 (IIV3 by IM route) (<xref rid="pone.0222178.t001" ref-type="table">Table 1</xref>).</p>
                <p>Following IIV3 administration via the ID route, the DNA-IIV3 regimen displayed a significant increase compared to a single administration of IIV3 in both the magnitude of the antibody response and the seroconversion rates for B/Texas/6/11 (p values of 0.008 and 0.038, respectively), and the seroconversion rates for A/Victoria/361/11 (p value of 0.040) (groups 1 and 3, <xref ref-type="fig" rid="pone.0222178.g002">Fig 2A</xref>). The DNA-IIV3 regimen by the ID route also trended towards increased antibody responses compared to a single administration of IIV3 for all strains tested, although these differences were not statistically significant (groups 1 and 3, <xref ref-type="fig" rid="pone.0222178.g002">Fig 2A</xref>).</p>
                <fig id="pone.0222178.g002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0222178.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Magnitude and frequency of antibody responses at three weeks after IIV3 administration for DNA-IIV3 prime-boost, IIV3 prime, or concurrent DNA/IIV3 prime.</title>
                    <p>The antibody responses were measured for the (A) ID route and (B) IM route by hemagglutination inhibition assay (HAI) and are displayed by group geometric mean titers (GMT) or group seroconversion rates for all 2012/13 vaccine strains, with error bars indicating the 95% CI. Comparisons were made between vaccine regimens for each route. Displayed p values for seroconversion rates were calculated based on Fisher’s Exact test, while GMT comparisons were based on pairwise T-test.</p>
                  </caption>
                  <graphic xlink:href="pone.0222178.g002"/>
                </fig>
                <p>For regimens administering IIV3 by the IM route, a single administration of IIV3 displayed a significantly higher seroconversion rate compared to the DNA-IIV3 regimen for B/Wisconsin/1/10 (p = 0.018) (groups 2 and 4, <xref ref-type="fig" rid="pone.0222178.g002">Fig 2B</xref>). A single administration of IIV3 also trended towards higher antibody responses compared to DNA-IIV3 for all other strains tested, although these differences were not statistically significant (groups 2 and 4, <xref ref-type="fig" rid="pone.0222178.g002">Fig 2B</xref>).</p>
              </sec>
              <sec id="sec017">
                <title>Concurrent administration of DNA and IIV3 did not result in improved antibody responses compared to IIV3 alone</title>
                <p>We also included a regimen in the trial with a prime vaccination that included a concurrent administration of DNA and IIV3 (DNA/IIV3) to assess whether simultaneous vaccination with DNA and IIV3 in separate arms could improve antibody responses compared with IIV3 (<xref rid="pone.0222178.t001" ref-type="table">Table 1</xref>). This would allow for a single annual vaccination visit rather than a prime-boost regimen requiring two separate visits. Similar to the other vaccine regimens, the IIV3 was administered by either ID route (group 5) or IM route (group 6). Our analysis at 3 weeks following the prime vaccination suggest that administering DNA and IIV3 concurrently did not result in a consistently improved immune response over a single administration of IIV3 by either route (<xref ref-type="fig" rid="pone.0222178.g002">Fig 2</xref>).</p>
              </sec>
              <sec id="sec018">
                <title>The DNA-IIV3 regimen by ID route and the IIV3-IIV3 regimen by IM route obtained the highest antibody responses after boost</title>
                <p>While DNA priming provides an optimal antibody response with a prime-boost interval between 3–6 months [<xref rid="pone.0222178.ref020" ref-type="bibr">20</xref>], inactivated influenza vaccines are typically given on an annual basis. In order to compare the prime-boost responses of the DNA-IIV3 regimen to a more traditional IIV3 prime-boost schedule, the groups that received a prime administration of IIV3 (groups 3–6) were boosted with a second IIV3 during the subsequent 2013/14 influenza season, with an interval of approximately 10 months (<xref rid="pone.0222178.t001" ref-type="table">Table 1</xref>). For each group, the IIV3 boost was administered through the same route as the initial IIV3. We then compared the antibody responses by HAI for the three completed vaccine regimens (DNA-IIV3, IIV3-IIV3, and DNA/IIV3-IIV3) at 3 weeks post boost (<xref ref-type="fig" rid="pone.0222178.g003">Fig 3</xref>).</p>
                <fig id="pone.0222178.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0222178.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Vaccine regimen comparison of magnitude and frequency of antibody response at 3 weeks post boost.</title>
                    <p>The GMT and seroconversion rates are shown for antibody responses measured by HAI for all 2012/13 and 2013/14 vaccine strains for the (A) ID route and (B) IM route, with error bars indicating the 95% CI. Comparisons were made between vaccine regimens for each route. Displayed p values for seroconversion rates were calculated based on Fisher’s Exact test, while GMT comparisons were based on pairwise T-test.</p>
                  </caption>
                  <graphic xlink:href="pone.0222178.g003"/>
                </fig>
                <p>The DNA-IIV3 regimen by the ID route resulted in significantly higher antibody titers and seroconversion rates compared to the other two vaccine regimens against the influenza B strains: B/Texas/6/11 (overall p values of &lt;0.001 and 0.020, respectively) and B/Massachusetts/2/12 (overall p values of &lt;0.001and 0.033, respectively), and a significantly higher magnitude of antibody response for B/Wisconsin/1/10 (overall p = 0.020) (<xref ref-type="fig" rid="pone.0222178.g003">Fig 3A</xref>). The magnitude of antibody response continued to be significantly increased at 6 months post boost for B/Texas/6/11 and B/Massachusetts/2/12 (overall p = 0.012 for both) (<xref ref-type="supplementary-material" rid="pone.0222178.s006">S3 Table</xref>). No differences were noted in the antibody responses for the influenza A strains between regimens.</p>
                <p>Among the regimens where IIV3 was administered by the IM route, the IIV3-IIV3 regimen showed higher seroconversion rates compared to the DNA-IIV3 regimen for the H3N2 strains A/Victoria/361/11 (p = 0.002) and A/Texas/50/12 (p = 0.021), as well as B/Wisconsin/1/10 (p = 0.021) (<xref ref-type="fig" rid="pone.0222178.g003">Fig 3B</xref>). Therefore, the DNA-IIV3 regimen trended towards higher antibody responses in influenza B strains among the ID regimens and IIV3-IIV3 trended towards higher seroconversion after boost among the regimens where IIV3 was administered IM.</p>
              </sec>
              <sec id="sec019">
                <title>Administration of IIV3 by ID route was not always dose-sparing</title>
                <p>Antibody responses post boost were also evaluated by comparing the ID route to the IM route within each regimen. The ID route is intended to be dose-sparing by providing antibody responses comparable to IM administration while requiring less antigen per dose [<xref rid="pone.0222178.ref033" ref-type="bibr">33</xref>–<xref rid="pone.0222178.ref035" ref-type="bibr">35</xref>]. No consistent improvement in antibody responses was detected between routes for all regimens. However, when significant strain-specific differences were observed, the higher responses were found following IM administration (<xref ref-type="supplementary-material" rid="pone.0222178.s009">S1 Fig</xref>), indicating that the ID route was not always dose-sparing in this trial. These differences diminished by 6 months post boost (<xref ref-type="supplementary-material" rid="pone.0222178.s005">S2</xref> and <xref ref-type="supplementary-material" rid="pone.0222178.s006">S3</xref> Tables). Interestingly, in regimens with a DNA only prime (groups 1 and 2), there were no significant differences between IM and ID groups, suggesting that a DNA only prime may augment responses to the low-dose antigen of an IIV3 ID boost.</p>
              </sec>
              <sec id="sec020">
                <title>Neither DNA prime nor ID route improved the vaccine response in older adults</title>
                <p>Since IIV3 can be less effective in the older population, we also compared the antibody responses between the younger (18–50 years) and older (51+ years) age groups within each vaccination regimen. In general, there were significantly increased antibody titers and seroconversion rates in the younger population when compared to the older population, at all time points measured (<xref ref-type="supplementary-material" rid="pone.0222178.s007">S4</xref> and <xref ref-type="supplementary-material" rid="pone.0222178.s008">S5</xref> Tables). These results are consistent with previous studies using DNA vaccines to prime subsequent boosting with conventional inactivated influenza vaccines [<xref rid="pone.0222178.ref022" ref-type="bibr">22</xref>].</p>
                <p>We were also interested in determining whether DNA priming would improve the antibody response in older adults. For this analysis, we examined the antibody responses of the three vaccine regimens in the older adults at time points throughout the clinical trial (<xref ref-type="fig" rid="pone.0222178.g004">Fig 4</xref>, <xref ref-type="supplementary-material" rid="pone.0222178.s007">S4</xref> and <xref ref-type="supplementary-material" rid="pone.0222178.s008">S5</xref> Tables). There was no overall improvement at any time point, suggesting that none of the tested regimens resulted in consistently improved antibody responses in older adults. Therefore, neither the addition of a DNA prime with a shorter prime-boost interval nor a concurrent DNA/IIV3 prime with a longer prime-boost interval improved the antibody response in the older population.</p>
                <fig id="pone.0222178.g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0222178.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>Magnitude and frequency of antibody response at 3 weeks post boost in older adults.</title>
                    <p>The GMT and seroconversion rates are shown for antibody responses measured by HAI for all 2012/13 and 2013/14 vaccine strains in older adults following (A) ID route and (B) IM route, with error bars indicating the 95% CI. Comparisons were made between vaccine regimens for each route. Displayed p values for seroconversion rates were calculated based on Fisher’s Exact test, while GMT comparisons were based on pairwise T-test.</p>
                  </caption>
                  <graphic xlink:href="pone.0222178.g004"/>
                </fig>
                <p>Antibody responses in the older population were also compared by route of administration at 3 weeks post boost. We did not observe any effect of age on the route comparison due to the different FDA-approved age ranges for IIV3 administration routes in the older adults. Generally, both the magnitude of the antibody response and the seroconversion rates were similar between administration routes for each regimen (<xref ref-type="supplementary-material" rid="pone.0222178.s010">S2 Fig</xref>). Similar to our observations for the entire study population, when differences were observed, IM administration resulted in higher responses compared to ID administration, suggesting that administration of IIV3 by ID route was not always dose-sparing in these subjects unless they were primed with DNA.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec021">
              <title>Discussion</title>
              <p>In this phase 1 open-label randomized clinical trial, we assessed the safety and tolerability of multiple seasonal influenza vaccination regimens in healthy adults. Local reactogenicity was mild to moderate in severity, with higher frequencies of pain/tenderness, swelling, and redness following DNA vaccination by Biojector compared to IIV3 by either administration route, and higher frequencies of redness and swelling following IIV3 administration by the ID route compared to the IM route. These findings are consistent with previous clinical trials [<xref rid="pone.0222178.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0222178.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0222178.ref036" ref-type="bibr">36</xref>]. Overall, all vaccine regimens were found to be safe and well tolerated. We also found that variables including priming vaccines, prime-boost intervals, and administration routes did not consistently impact the antibody response following an IIV3 boost in healthy adults who had substantial levels of preexisting immunity to the vaccine antigens used in this study. A limitation to this study is the small trial size, which is typical of phase 1 clinical trials.</p>
              <p>While the antibody responses between the different vaccination regimens did not differ overall, we did observe several trends that remained consistent throughout the trial. After each IIV3 administration we observed the highest antibody responses in the DNA-IIV3 group when IIV3 was administered by the ID route (group 1), and the IIV3-IIV3 group when IIV3 was administered by the IM route (group 4). The observed trend in group 1 may indicate that ID is the preferred route for IIV3 administration following a DNA prime, but only when paired with an optimal prime-boost interval of 3–6 months. If the boost occurs outside of this window, our data suggest that an inactivated prime delivered by IM may provide a superior response. Interestingly, a difference in antibody response was not observed between the concurrent DNA/IIV3-IIV3 regimen by ID route (group 5) or IM route (group 6), perhaps due to immune interference or the prolonged prime-boost interval. Even when compared to a single IIV3, concurrent administrations of DNA and IIV3 did not improve the antibody response, confirming that a DNA prime must be paired with an appropriately timed boost to achieve optimal immunogenicity. This finding suggests that DNA priming establishes a distinct population of responsive memory B cells that are not induced or sustained in the same way by immunization with protein as in the IIV3.</p>
              <p>The subjects in group 1 who received the DNA-IIV3 regimen by ID route had significantly higher antibody responses to the influenza B strains B/Wisconsin/1/2010 and B/Texas/6/2011 compared to the other vaccine regimens administered by the ID route. These subjects also exhibited an increased response to the 2013/14 strain B/Massachusetts/2/12, even though this strain was not included in either 2012/13 vaccine product. Since all of the B strains in this trial are of the Yamagata lineage, one possible explanation is that DNA priming allowed for an increased breadth of antibody response against drifted influenza B strains. In a previous trial examining seasonal influenza vaccination with a DNA prime followed by an IIV3 boost, a significant antibody increase was not observed for the influenza B strains tested [<xref rid="pone.0222178.ref022" ref-type="bibr">22</xref>]. However, that trial included a DNA prime with an influenza B strain of the Victoria lineage while the IIV3 boost contained a B strain from the Yamagata lineage. Therefore, DNA priming may induce memory B cells against influenza B that are strain-specific and are not boosted well by antigenically varied vaccines.</p>
              <p>In this trial, we did not observe a regimen that was superior for the older population. DNA vaccines have been a strategy of interest in older adults because they are believed to not only expand memory B cell populations, but also induce a variety of T cell responses [<xref rid="pone.0222178.ref037" ref-type="bibr">37</xref>–<xref rid="pone.0222178.ref039" ref-type="bibr">39</xref>]. While we did not directly analyze T cell responses in this study, the regimens that included a DNA prime did not result in significantly improved antibody responses in the older adults. Multiple studies comparing ID and IM routes of administration for inactivated influenza vaccines in older adults have shown comparable immunogenicity outcomes [<xref rid="pone.0222178.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0222178.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0222178.ref041" ref-type="bibr">41</xref>]; whereas we observed that the ID route for IIV3 was not always dose-sparing in this trial. However, this phase 1 trial was small in size and not designed with dose-escalations within the ID or IM routes, and therefore not powered for a more conclusive analysis of this observation. Currently, high-dose IIV3 via the IM route (0.5mL, 180 μg total HA) is recommended for older adults because it has been shown to improve immunogenicity via both ID and IM routes [<xref rid="pone.0222178.ref041" ref-type="bibr">41</xref>–<xref rid="pone.0222178.ref043" ref-type="bibr">43</xref>]. Future studies might consider incorporating DNA priming with high-dose IIV3 boosting, and include an assessment of T cell responses, to further evaluate whether DNA priming could improve immunogenicity in the older population.</p>
              <p>Since this clinical trial began in 2012 there have been several advances for both DNA and influenza vaccines. Additional clinical trials have been published for DNA vaccines, providing further proof of the safety and immunogenicity of this vaccine platform [<xref rid="pone.0222178.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0222178.ref030" ref-type="bibr">30</xref>], and preclinical studies have begun evaluating novel delivery routes including microneedle patches [<xref rid="pone.0222178.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0222178.ref045" ref-type="bibr">45</xref>]. Several new influenza vaccines have also become licensed, including a quadrivalent version of the seasonal inactivated vaccine [<xref rid="pone.0222178.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0222178.ref007" ref-type="bibr">7</xref>]. This clinical trial began before the quadrivalent vaccine became commercially available, and we were therefore unable to include the IIV4 in our evaluation. However, we predict the IIV4 would result in similar trends as we observed with the IIV3, while possibly providing increased protection against more antigenically drifted influenza B strains.</p>
              <p>In summary, we found that all vaccine regimens in the study were safe and well tolerated. We did not observe any consistent improvement in antibody responses by varying the priming vaccination, prime-boost interval, or administration route for IIV3 in this phase 1 study in healthy adults. In the older population, the addition of a DNA prime did not improve the antibody response following an IIV3 boost, but future studies may be warranted to assess responses if paired with a high-dose IIV3.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec022">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0222178.s001">
                <label>S1 CONSORT Checklist</label>
                <caption>
                  <title>CONSORT checklist for VRC 703 clinical trial.</title>
                  <p>(DOC)</p>
                </caption>
                <media xlink:href="pone.0222178.s001.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s002">
                <label>S1 Protocol</label>
                <caption>
                  <title>VRC 703 clinical trial protocol.</title>
                  <p>Protocol version before enrollment.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0222178.s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s003">
                <label>S2 Protocol</label>
                <caption>
                  <title>VRC 703 clinical trial protocol.</title>
                  <p>Final protocol version.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0222178.s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s004">
                <label>S1 Table</label>
                <caption>
                  <title>Summary of solicited systemic reactogenicity after prime and boost vaccination.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0222178.s004.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s005">
                <label>S2 Table</label>
                <caption>
                  <title>Seroconversion rates for study groups as measured by HAI.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0222178.s005.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s006">
                <label>S3 Table</label>
                <caption>
                  <title>Magnitude of antibody responses for study groups as measured by HAI.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0222178.s006.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s007">
                <label>S4 Table</label>
                <caption>
                  <title>Magnitude of antibody responses for age subgroups as measured by HAI.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0222178.s007.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s008">
                <label>S5 Table</label>
                <caption>
                  <title>Seroconversion rates for age subgroups as measured by HAI.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0222178.s008.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s009">
                <label>S1 Fig</label>
                <caption>
                  <title>Route comparison of magnitude and frequency of antibody response in all subjects post boost.</title>
                  <p>(A) GMT and (B) seroconversion rates are shown for antibody responses measured by HAI at 3 weeks post boost for all 2012/13 and 2013/14 vaccine strains, with error bars indicating the 95% CI. For each vaccination regimen results are displayed for both the ID (blue) and IM (red) routes. Comparisons were made between administration routes for each vaccine regimen. Displayed p values for seroconversion rates were calculated based on Fisher’s Exact test, while GMT comparisons were based on pairwise T-test.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0222178.s009.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s010">
                <label>S2 Fig</label>
                <caption>
                  <title>Route comparison of magnitude and frequency of antibody response in the older adult subgroups post boost.</title>
                  <p>(A) GMT and (B) seroconversion rates are shown for antibody responses measured by HAI at 3 weeks post boost for all 2012/13 and 2013/14 vaccine strains, with error bars indicating the 95% CI. For each vaccination regimen results are displayed for both the ID (blue) and IM (red) routes. Comparisons were made between administration routes for each vaccine regimen. Displayed p values for seroconversion rates were calculated based on Fisher’s Exact test, while GMT comparisons were based on pairwise T-test.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0222178.s010.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0222178.s011">
                <label>S1 Data</label>
                <caption>
                  <title>Raw data from VRC 703 clinical trial.</title>
                  <p>(XLSX)</p>
                </caption>
                <media xlink:href="pone.0222178.s011.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The VRC 703 Study Team: Joseph Casazza (study team lead, email: <email>jcasazza@mail.nih.gov</email>), Richard Schwartz, Michelle Conan-Cibotti, and Florence Kaltovich from the VRC, and Amy Bray, Thad Zajdowicz, Robert Lindblad, Phyllis Renehan, and Jamie Winestone from the Emmes Corporation.</p>
              <p>We would also like to thank Stanford Vaccine Program staff S. Mackey, S. Swope, N. Mastman, T. Trela, T. Quan, A. Goel, and M. Ugur, Baylor College of Medicine staff Celsa Tajonera, the BCM Vaccine Research Center clinical and laboratory staff, the study volunteers for their time and participation, the Emmes Corporation, the VRC, NIAID, and supporting staff who have made this work possible.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0222178.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Reed</surname><given-names>C</given-names></name>, <name><surname>Chaves</surname><given-names>SS</given-names></name>, <name><surname>Daily Kirley</surname><given-names>P</given-names></name>, <name><surname>Emerson</surname><given-names>R</given-names></name>, <name><surname>Aragon</surname><given-names>D</given-names></name>, <name><surname>Hancock</surname><given-names>EB</given-names></name>, <etal>et al</etal><article-title>Estimating influenza disease burden from population-based surveillance data in the United States</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e0118369</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0118369</pub-id><?supplied-pmid 25738736?><pub-id pub-id-type="pmid">25738736</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Epperson</surname><given-names>S</given-names></name>, <name><surname>Blanton</surname><given-names>L</given-names></name>, <name><surname>Kniss</surname><given-names>K</given-names></name>, <name><surname>Mustaquim</surname><given-names>D</given-names></name>, <name><surname>Steffens</surname><given-names>C</given-names></name>, <name><surname>Wallis</surname><given-names>T</given-names></name>, <etal>et al</etal><article-title>Influenza activity—United States, 2013–14 season and composition of the 2014–15 influenza vaccines</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2014</year>;<volume>63</volume>(<issue>22</issue>):<fpage>483</fpage>–<lpage>90</lpage>. <?supplied-pmid 24898165?><pub-id pub-id-type="pmid">24898165</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Mullooly</surname><given-names>JP</given-names></name>, <name><surname>Bridges</surname><given-names>CB</given-names></name>, <name><surname>Thompson</surname><given-names>WW</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Weintraub</surname><given-names>E</given-names></name>, <name><surname>Jackson</surname><given-names>LA</given-names></name>, <etal>et al</etal><article-title>Influenza- and RSV-associated hospitalizations among adults</article-title>. <source>Vaccine</source>. <year>2007</year>;<volume>25</volume>(<issue>5</issue>):<fpage>846</fpage>–<lpage>55</lpage>. <?supplied-pmid 17074423?><pub-id pub-id-type="pmid">17074423</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Molinari</surname><given-names>NA</given-names></name>, <name><surname>Ortega-Sanchez</surname><given-names>IR</given-names></name>, <name><surname>Messonnier</surname><given-names>ML</given-names></name>, <name><surname>Thompson</surname><given-names>WW</given-names></name>, <name><surname>Wortley</surname><given-names>PM</given-names></name>, <name><surname>Weintraub</surname><given-names>E</given-names></name>, <etal>et al</etal><article-title>The annual impact of seasonal influenza in the US: measuring disease burden and costs</article-title>. <source>Vaccine</source>. <year>2007</year>;<volume>25</volume>(<issue>27</issue>):<fpage>5086</fpage>–<lpage>96</lpage>. <?supplied-pmid 17544181?><pub-id pub-id-type="pmid">17544181</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Grohskopf</surname><given-names>LA</given-names></name>, <name><surname>Sokolow</surname><given-names>LZ</given-names></name>, <name><surname>Broder</surname><given-names>KR</given-names></name>, <name><surname>Walter</surname><given-names>EB</given-names></name>, <name><surname>Fry</surname><given-names>AM</given-names></name>, <name><surname>Jernigan</surname><given-names>DB</given-names></name>. <article-title>Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018–19 Influenza Season</article-title>. <source>MMWR Recomm Rep</source>. <year>2018</year>;<volume>67</volume>(<issue>3</issue>):<fpage>1</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.rr6703a1</pub-id>
<?supplied-pmid 30141464?><pub-id pub-id-type="pmid">30141464</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Palache</surname><given-names>A</given-names></name>, <name><surname>Oriol-Mathieu</surname><given-names>V</given-names></name>, <name><surname>Abelin</surname><given-names>A</given-names></name>, <name><surname>Music</surname><given-names>T</given-names></name>, <article-title>Influenza Vaccine Supply task f. Seasonal influenza vaccine dose distribution in 157 countries (2004–2011)</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>48</issue>):<fpage>6369</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.07.012</pub-id>
<?supplied-pmid 25442403?><pub-id pub-id-type="pmid">25442403</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref007">
                <label>7</label>
                <mixed-citation publication-type="other">FDA. Influenza Virus Vaccine, Quadrivalent, Types A and Types B 2019 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-virus-vaccine-quadrivalent-types-and-types-b">https://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-virus-vaccine-quadrivalent-types-and-types-b</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0222178.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Ray</surname><given-names>R</given-names></name>, <name><surname>Dos Santos</surname><given-names>G</given-names></name>, <name><surname>Buck</surname><given-names>PO</given-names></name>, <name><surname>Claeys</surname><given-names>C</given-names></name>, <name><surname>Matias</surname><given-names>G</given-names></name>, <name><surname>Innis</surname><given-names>BL</given-names></name>, <etal>et al</etal><article-title>A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control</article-title>. <source>Hum Vaccin Immunother</source>. <year>2017</year>;<volume>13</volume>(<issue>7</issue>):<fpage>1640</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2017.1313375</pub-id>
<?supplied-pmid 28532276?><pub-id pub-id-type="pmid">28532276</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref009">
                <label>9</label>
                <mixed-citation publication-type="other">FDA. Approval Letter—Fluzone Intradermal 2011 [Available from: <ext-link ext-link-type="uri" xlink:href="http://wayback.archive-it.org/7993/20170723030613/">http://wayback.archive-it.org/7993/20170723030613/</ext-link><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm255160.htm">https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm255160.htm</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0222178.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Osterholm</surname><given-names>MT</given-names></name>, <name><surname>Kelley</surname><given-names>NS</given-names></name>, <name><surname>Sommer</surname><given-names>A</given-names></name>, <name><surname>Belongia</surname><given-names>EA</given-names></name>. <article-title>Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis</article-title>. <source>Lancet Infect Dis</source>. <year>2012</year>;<volume>12</volume>(<issue>1</issue>):<fpage>36</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(11)70295-X</pub-id>
<?supplied-pmid 22032844?><pub-id pub-id-type="pmid">22032844</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Jefferson</surname><given-names>T</given-names></name>, <name><surname>Di Pietrantonj</surname><given-names>C</given-names></name>, <name><surname>Al-Ansary</surname><given-names>LA</given-names></name>, <name><surname>Ferroni</surname><given-names>E</given-names></name>, <name><surname>Thorning</surname><given-names>S</given-names></name>, <name><surname>Thomas</surname><given-names>RE</given-names></name>. <article-title>Vaccines for preventing influenza in the elderly</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2010</year>(<issue>2</issue>):<fpage>CD004876</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD004876.pub3</pub-id><?supplied-pmid 20166072?><pub-id pub-id-type="pmid">20166072</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Jefferson</surname><given-names>T</given-names></name>, <name><surname>Di Pietrantonj</surname><given-names>C</given-names></name>, <name><surname>Rivetti</surname><given-names>A</given-names></name>, <name><surname>Bawazeer</surname><given-names>GA</given-names></name>, <name><surname>Al-Ansary</surname><given-names>LA</given-names></name>, <name><surname>Ferroni</surname><given-names>E</given-names></name>. <article-title>Vaccines for preventing influenza in healthy adults</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2010</year>(<issue>7</issue>):<fpage>CD001269</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD001269.pub4</pub-id><?supplied-pmid 20614424?><pub-id pub-id-type="pmid">20614424</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Zimmerman</surname><given-names>RK</given-names></name>, <name><surname>Nowalk</surname><given-names>MP</given-names></name>, <name><surname>Chung</surname><given-names>J</given-names></name>, <name><surname>Jackson</surname><given-names>ML</given-names></name>, <name><surname>Jackson</surname><given-names>LA</given-names></name>, <name><surname>Petrie</surname><given-names>JG</given-names></name>, <etal>et al</etal><article-title>2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type</article-title>. <source>Clin Infect Dis</source>. <year>2016</year>;<volume>63</volume>(<issue>12</issue>):<fpage>1564</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciw635</pub-id>
<?supplied-pmid 27702768?><pub-id pub-id-type="pmid">27702768</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Houser</surname><given-names>K</given-names></name>, <name><surname>Subbarao</surname><given-names>K</given-names></name>. <article-title>Influenza vaccines: challenges and solutions</article-title>. <source>Cell Host Microbe</source>. <year>2015</year>;<volume>17</volume>(<issue>3</issue>):<fpage>295</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2015.02.012</pub-id>
<?supplied-pmid 25766291?><pub-id pub-id-type="pmid">25766291</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref015">
                <label>15</label>
                <mixed-citation publication-type="other">CDC. Influenza vaccines—United States, 2018–19 influenza season 2019 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/professionals/vaccines.htm">https://www.cdc.gov/flu/professionals/vaccines.htm</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0222178.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Ledgerwood</surname><given-names>JE</given-names></name>, <name><surname>Graham</surname><given-names>BS</given-names></name>. <article-title>DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases</article-title>. <source>Hum Vaccin</source>. <year>2009</year>;<volume>5</volume>(<issue>9</issue>):<fpage>623</fpage>–<lpage>6</lpage>. <?supplied-pmid 19779298?><pub-id pub-id-type="pmid">19779298</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>DeZure</surname><given-names>AD</given-names></name>, <name><surname>Coates</surname><given-names>EE</given-names></name>, <name><surname>Hu</surname><given-names>Z</given-names></name>, <name><surname>Yamshchikov</surname><given-names>GV</given-names></name>, <name><surname>Zephir</surname><given-names>KL</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <etal>et al</etal><article-title>An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial</article-title>. <source>npj Vaccines</source>. <year>2017</year>;<volume>2</volume>(<issue>1</issue>):<fpage>15</fpage>.<pub-id pub-id-type="pmid">29263871</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Ledgerwood</surname><given-names>JE</given-names></name>, <name><surname>Hu</surname><given-names>Z</given-names></name>, <name><surname>Gordon</surname><given-names>IJ</given-names></name>, <name><surname>Yamshchikov</surname><given-names>G</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <name><surname>Plummer</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans</article-title>. <source>Clin Vaccine Immunol</source>. <year>2012</year>;<volume>19</volume>(<issue>11</issue>):<fpage>1792</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.05663-11</pub-id>
<?supplied-pmid 22956656?><pub-id pub-id-type="pmid">22956656</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Ledgerwood</surname><given-names>JE</given-names></name>, <name><surname>Wei</surname><given-names>CJ</given-names></name>, <name><surname>Hu</surname><given-names>Z</given-names></name>, <name><surname>Gordon</surname><given-names>IJ</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <name><surname>Hendel</surname><given-names>CS</given-names></name>, <etal>et al</etal><article-title>DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials</article-title>. <source>Lancet Infect Dis</source>. <year>2011</year>;<volume>11</volume>(<issue>12</issue>):<fpage>916</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(11)70240-7</pub-id>
<?supplied-pmid 21975270?><pub-id pub-id-type="pmid">21975270</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Ledgerwood</surname><given-names>JE</given-names></name>, <name><surname>Zephir</surname><given-names>K</given-names></name>, <name><surname>Hu</surname><given-names>Z</given-names></name>, <name><surname>Wei</surname><given-names>CJ</given-names></name>, <name><surname>Chang</surname><given-names>L</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <etal>et al</etal><article-title>Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect</article-title>. <source>J Infect Dis</source>. <year>2013</year>;<volume>208</volume>(<issue>3</issue>):<fpage>418</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit180</pub-id>
<?supplied-pmid 23633407?><pub-id pub-id-type="pmid">23633407</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Houser</surname><given-names>KV</given-names></name>, <name><surname>Yamshchikov</surname><given-names>GV</given-names></name>, <name><surname>Bellamy</surname><given-names>AR</given-names></name>, <name><surname>May</surname><given-names>J</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <name><surname>Sarwar</surname><given-names>U</given-names></name>, <etal>et al</etal><article-title>DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial</article-title>. <source>PLoS One</source>. <year>2018</year>;<volume>13</volume>(<issue>11</issue>):<fpage>e0206837</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0206837</pub-id><?supplied-pmid 30388160?><pub-id pub-id-type="pmid">30388160</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Ledgerwood</surname><given-names>JE</given-names></name>, <name><surname>Bellamy</surname><given-names>AR</given-names></name>, <name><surname>Belshe</surname><given-names>R</given-names></name>, <name><surname>Bernstein</surname><given-names>DI</given-names></name>, <name><surname>Edupuganti</surname><given-names>S</given-names></name>, <name><surname>Patel</surname><given-names>SM</given-names></name>, <etal>et al</etal><article-title>DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e0125914</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0125914</pub-id><?supplied-pmid 25950433?><pub-id pub-id-type="pmid">25950433</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Crank</surname><given-names>MC</given-names></name>, <name><surname>Gordon</surname><given-names>IJ</given-names></name>, <name><surname>Yamshchikov</surname><given-names>GV</given-names></name>, <name><surname>Sitar</surname><given-names>S</given-names></name>, <name><surname>Hu</surname><given-names>Z</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <etal>et al</etal><article-title>Phase 1 study of pandemic H1 DNA vaccine in healthy adults</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>4</issue>):<fpage>e0123969</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0123969</pub-id><?supplied-pmid 25884189?><pub-id pub-id-type="pmid">25884189</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Gaudinski</surname><given-names>MR</given-names></name>, <name><surname>Houser</surname><given-names>KV</given-names></name>, <name><surname>Morabito</surname><given-names>KM</given-names></name>, <name><surname>Hu</surname><given-names>Z</given-names></name>, <name><surname>Yamshchikov</surname><given-names>G</given-names></name>, <name><surname>Rothwell</surname><given-names>RS</given-names></name>, <etal>et al</etal><article-title>Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>(<issue>10120</issue>):<fpage>552</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)33105-7</pub-id>
<?supplied-pmid 29217376?><pub-id pub-id-type="pmid">29217376</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Graham</surname><given-names>BS</given-names></name>, <name><surname>Koup</surname><given-names>RA</given-names></name>, <name><surname>Roederer</surname><given-names>M</given-names></name>, <name><surname>Bailer</surname><given-names>RT</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <name><surname>Moodie</surname><given-names>Z</given-names></name>, <etal>et al</etal><article-title>Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine</article-title>. <source>J Infect Dis</source>. <year>2006</year>;<volume>194</volume>(<issue>12</issue>):<fpage>1650</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1086/509259</pub-id>
<?supplied-pmid 17109336?><pub-id pub-id-type="pmid">17109336</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Ledgerwood</surname><given-names>JE</given-names></name>, <name><surname>Hu</surname><given-names>Z</given-names></name>, <name><surname>Costner</surname><given-names>P</given-names></name>, <name><surname>Yamshchikov</surname><given-names>G</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <name><surname>Plummer</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost</article-title>. <source>Contemp Clin Trials</source>. <year>2015</year>;<volume>44</volume>:<fpage>112</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2015.08.006</pub-id>
<?supplied-pmid 26275339?><pub-id pub-id-type="pmid">26275339</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>JE</given-names></name>, <name><surname>Louder</surname><given-names>MK</given-names></name>, <name><surname>Holman</surname><given-names>LA</given-names></name>, <name><surname>Gordon</surname><given-names>IJ</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <name><surname>Larkin</surname><given-names>BD</given-names></name>, <etal>et al</etal><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title>. <source>Vaccine</source>. <year>2008</year>;<volume>26</volume>(<issue>50</issue>):<fpage>6338</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.09.026</pub-id>
<?supplied-pmid 18824060?><pub-id pub-id-type="pmid">18824060</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>JE</given-names></name>, <name><surname>Pierson</surname><given-names>TC</given-names></name>, <name><surname>Hubka</surname><given-names>S</given-names></name>, <name><surname>Rucker</surname><given-names>S</given-names></name>, <name><surname>Gordon</surname><given-names>IJ</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <etal>et al</etal><article-title>A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial</article-title>. <source>J Infect Dis</source>. <year>2007</year>;<volume>196</volume>(<issue>12</issue>):<fpage>1732</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1086/523650</pub-id>
<?supplied-pmid 18190252?><pub-id pub-id-type="pmid">18190252</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>JE</given-names></name>, <name><surname>Sullivan</surname><given-names>NJ</given-names></name>, <name><surname>Enama</surname><given-names>ME</given-names></name>, <name><surname>Gordon</surname><given-names>IJ</given-names></name>, <name><surname>Roederer</surname><given-names>M</given-names></name>, <name><surname>Koup</surname><given-names>RA</given-names></name>, <etal>et al</etal><article-title>A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial</article-title>. <source>Clin Vaccine Immunol</source>. <year>2006</year>;<volume>13</volume>(<issue>11</issue>):<fpage>1267</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00162-06</pub-id>
<?supplied-pmid 16988008?><pub-id pub-id-type="pmid">16988008</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Tebas</surname><given-names>P</given-names></name>, <name><surname>Roberts</surname><given-names>CC</given-names></name>, <name><surname>Muthumani</surname><given-names>K</given-names></name>, <name><surname>Reuschel</surname><given-names>EL</given-names></name>, <name><surname>Kudchodkar</surname><given-names>SB</given-names></name>, <name><surname>Zaidi</surname><given-names>FI</given-names></name>, <etal>et al</etal><article-title>Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine—Preliminary Report</article-title>. <source>N Engl J Med</source>. <year>2017</year>.</mixed-citation>
              </ref>
              <ref id="pone.0222178.ref031">
                <label>31</label>
                <mixed-citation publication-type="other">FDA. Approval Letter- Fluzone 2012 [Available from: <ext-link ext-link-type="uri" xlink:href="http://wayback.archive-it.org/7993/20170723030605/">http://wayback.archive-it.org/7993/20170723030605/</ext-link><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm310580.htm">https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm310580.htm</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0222178.ref032">
                <label>32</label>
                <mixed-citation publication-type="other">FDA. Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. U. S. DHHS, FDA, CBER.; 2007.</mixed-citation>
              </ref>
              <ref id="pone.0222178.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Frenck</surname><given-names>RW</given-names><suffix>Jr.</suffix></name>, <name><surname>Belshe</surname><given-names>R</given-names></name>, <name><surname>Brady</surname><given-names>RC</given-names></name>, <name><surname>Winokur</surname><given-names>PL</given-names></name>, <name><surname>Campbell</surname><given-names>JD</given-names></name>, <name><surname>Treanor</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults</article-title>. <source>Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>34</issue>):<fpage>5666</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.010</pub-id>
<?supplied-pmid 21699951?><pub-id pub-id-type="pmid">21699951</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Gorse</surname><given-names>GJ</given-names></name>, <name><surname>Falsey</surname><given-names>AR</given-names></name>, <name><surname>Fling</surname><given-names>JA</given-names></name>, <name><surname>Poling</surname><given-names>TL</given-names></name>, <name><surname>Strout</surname><given-names>CB</given-names></name>, <name><surname>Tsang</surname><given-names>PH</given-names></name>. <article-title>Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18–64 years of age</article-title>. <source>Vaccine</source>. <year>2013</year>;<volume>31</volume>(<issue>19</issue>):<fpage>2358</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.03.008</pub-id>
<?supplied-pmid 23499604?><pub-id pub-id-type="pmid">23499604</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Gorse</surname><given-names>GJ</given-names></name>, <name><surname>Falsey</surname><given-names>AR</given-names></name>, <name><surname>Johnson</surname><given-names>CM</given-names></name>, <name><surname>Morrison</surname><given-names>D</given-names></name>, <name><surname>Fried</surname><given-names>DL</given-names></name>, <name><surname>Ervin</surname><given-names>JE</given-names></name>, <etal>et al</etal><article-title>Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age</article-title>. <source>Vaccine</source>. <year>2013</year>;<volume>31</volume>(<issue>50</issue>):<fpage>6034</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.09.012</pub-id>
<?supplied-pmid 24055306?><pub-id pub-id-type="pmid">24055306</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Marra</surname><given-names>F</given-names></name>, <name><surname>Young</surname><given-names>F</given-names></name>, <name><surname>Richardson</surname><given-names>K</given-names></name>, <name><surname>Marra</surname><given-names>CA</given-names></name>. <article-title>A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2013</year>;<volume>7</volume>(<issue>4</issue>):<fpage>584</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12000</pub-id>
<?supplied-pmid 22974174?><pub-id pub-id-type="pmid">22974174</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>McElhaney</surname><given-names>JE</given-names></name>, <name><surname>Dutz</surname><given-names>JP</given-names></name>. <article-title>Better influenza vaccines for older people: what will it take?</article-title><source>J Infect Dis</source>. <year>2008</year>;<volume>198</volume>(<issue>5</issue>):<fpage>632</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1086/590435</pub-id>
<?supplied-pmid 18652548?><pub-id pub-id-type="pmid">18652548</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>McElhaney</surname><given-names>JE</given-names></name>, <name><surname>Xie</surname><given-names>D</given-names></name>, <name><surname>Hager</surname><given-names>WD</given-names></name>, <name><surname>Barry</surname><given-names>MB</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Kleppinger</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>T cell responses are better correlates of vaccine protection in the elderly</article-title>. <source>J Immunol</source>. <year>2006</year>;<volume>176</volume>(<issue>10</issue>):<fpage>6333</fpage>–<lpage>9</lpage>. <?supplied-pmid 16670345?><pub-id pub-id-type="pmid">16670345</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>LY</given-names></name>, <name><surname>Ha do</surname><given-names>LA</given-names></name>, <name><surname>Simmons</surname><given-names>C</given-names></name>, <name><surname>de Jong</surname><given-names>MD</given-names></name>, <name><surname>Chau</surname><given-names>NV</given-names></name>, <name><surname>Schumacher</surname><given-names>R</given-names></name>, <etal>et al</etal><article-title>Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals</article-title>. <source>J Clin Invest</source>. <year>2008</year>;<volume>118</volume>(<issue>10</issue>):<fpage>3478</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1172/JCI32460</pub-id>
<?supplied-pmid 18802496?><pub-id pub-id-type="pmid">18802496</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Young</surname><given-names>F</given-names></name>, <name><surname>Marra</surname><given-names>F</given-names></name>. <article-title>A systematic review of intradermal influenza vaccines</article-title>. <source>Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>48</issue>):<fpage>8788</fpage>–<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.077</pub-id>
<?supplied-pmid 21968444?><pub-id pub-id-type="pmid">21968444</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Tsang</surname><given-names>P</given-names></name>, <name><surname>Gorse</surname><given-names>GJ</given-names></name>, <name><surname>Strout</surname><given-names>CB</given-names></name>, <name><surname>Sperling</surname><given-names>M</given-names></name>, <name><surname>Greenberg</surname><given-names>DP</given-names></name>, <name><surname>Ozol-Godfrey</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Immunogenicity and safety of Fluzone((R)) intradermal and high-dose influenza vaccines in older adults &gt;/ = 65 years of age: a randomized, controlled, phase II trial</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>21</issue>):<fpage>2507</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.09.074</pub-id>
<?supplied-pmid 24120672?><pub-id pub-id-type="pmid">24120672</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>DiazGranados</surname><given-names>CA</given-names></name>, <name><surname>Dunning</surname><given-names>AJ</given-names></name>, <name><surname>Kimmel</surname><given-names>M</given-names></name>, <name><surname>Kirby</surname><given-names>D</given-names></name>, <name><surname>Treanor</surname><given-names>J</given-names></name>, <name><surname>Collins</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Efficacy of high-dose versus standard-dose influenza vaccine in older adults</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>(<issue>7</issue>):<fpage>635</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1315727</pub-id>
<?supplied-pmid 25119609?><pub-id pub-id-type="pmid">25119609</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Falsey</surname><given-names>AR</given-names></name>, <name><surname>Treanor</surname><given-names>JJ</given-names></name>, <name><surname>Tornieporth</surname><given-names>N</given-names></name>, <name><surname>Capellan</surname><given-names>J</given-names></name>, <name><surname>Gorse</surname><given-names>GJ</given-names></name>. <article-title>Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older</article-title>. <source>J Infect Dis</source>. <year>2009</year>;<volume>200</volume>(<issue>2</issue>):<fpage>172</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1086/599790</pub-id>
<?supplied-pmid 19508159?><pub-id pub-id-type="pmid">19508159</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>YC</given-names></name>, <name><surname>Song</surname><given-names>JM</given-names></name>, <name><surname>Lipatov</surname><given-names>AS</given-names></name>, <name><surname>Choi</surname><given-names>SO</given-names></name>, <name><surname>Lee</surname><given-names>JW</given-names></name>, <name><surname>Donis</surname><given-names>RO</given-names></name>, <etal>et al</etal><article-title>Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch</article-title>. <source>Eur J Pharm Biopharm</source>. <year>2012</year>;<volume>81</volume>(<issue>2</issue>):<fpage>239</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2012.03.010</pub-id>
<?supplied-pmid 22504442?><pub-id pub-id-type="pmid">22504442</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0222178.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>JM</given-names></name>, <name><surname>Kim</surname><given-names>YC</given-names></name>, <name><surname>O</surname><given-names>E</given-names></name>, <name><surname>Compans</surname><given-names>RW</given-names></name>, <name><surname>Prausnitz</surname><given-names>MR</given-names></name>, <name><surname>Kang</surname><given-names>SM</given-names></name>. <article-title>DNA vaccination in the skin using microneedles improves protection against influenza</article-title>. <source>Mol Ther</source>. <year>2012</year>;<volume>20</volume>(<issue>7</issue>):<fpage>1472</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2012.69</pub-id>
<?supplied-pmid 22508490?><pub-id pub-id-type="pmid">22508490</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
